Trials / Terminated
TerminatedNCT01092052
Study of NMS-1116354 in Advanced/Metastatic Solid Tumors
A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced/Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced/metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-1116354 | Oral daily administration for 14 consecutive days followed by 7 days of rest |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2012-07-01
- First posted
- 2010-03-24
- Last updated
- 2012-09-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01092052. Inclusion in this directory is not an endorsement.